Medical devices, healthcare technology and the business of care
510(k) clearance · K260781

Yumizen H550

HORIBA ABX SAS · Decision date Sep 14, 2026

MEDTECHLEDGER EXPLANATIONK260781

What did the FDA decide?

FDA recorded a substantially equivalent (SESE) decision on September 14, 2026 for K260781, the Yumizen H550 submitted by HORIBA ABX SAS of Montpellier, France. The device is an automated differential cell counter under 21 CFR 864.5220, Class II, product code GKZ, in the hematology panel. The submission is a traditional 510(k) for a new device, not a supplement, and the Safety and Effectiveness Summary describes the purpose as clearance for a new device. SESE means clearance to market, not PMA approval.

The stated indications cover classification and enumeration of a listed set of whole-blood parameters, including WBC, RBC, HGB, HCT, MCV, MCH, MCHC, RDW-CV, RDW-SD, PLT, MPV, and leukocyte subpopulation absolute and percentage counts through IMG%. Specimens are venous blood and capillary blood in K2-EDTA or K3-EDTA, for in vitro diagnostic use in clinical laboratories, with quantitative measurement and qualitative alarm detection. The record does not establish analytical performance, comparative accuracy, or clinical utility; the review document excerpt also references a different model, the Yumizen H2500, so its applicability to this decision is unclear.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Hematology
Decision date
Sep 14, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K260781
Regulatory pathway
510(k) premarket notification
Product code
GKZ
Decision code
SESE
Decision date
Sep 14, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Counter, Differential Cell.

Product code
GKZ
FDA device class
2

FDA decision timeline

  1. K260781 received

    Application receipt date recorded by FDA.

  2. K260781 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

No additional submissions with a verified PMA or product-code relationship are linked here.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

HORIBA ABX SAS

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Montpellier

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records